Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
Journal article
Hillson K. et al, (2021), Lancet, 398, 1683 - 1684
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Journal article
Folegatti PM. et al, (2019), Vaccines, 7, 33 - 33
Tuberculosis vaccines: present and future
Journal article
Minassian AM. and McShane H., (2008), Expert Review of Respiratory Medicine, 2, 721 - 738